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We examined the relationship between use of progestagen-only before menopause (except for mini-pills) after the age of 40 and
invasive breast cancer risk in 73664 women from the French E3N cohort study (mean age at start of follow-up, 51.8 years; mean
duration of follow-up, 9.1 years). A total of 2390 cases of invasive breast cancer were diagnosed during follow-up. Risk estimates
were calculated using the Cox proportional hazard model. Overall, ever use of progestagen before menopause was not significantly
associated with risk (relative risk (RR): 1.01, 95% confidence interval: 0.93–1.11). However, we observed a significant increase in risk
associated with the duration of use (P-value for trend: 0.012), current use of progestagens for longer than 4.5 years being significantly
associated with risk (RR: 1.44, 95% confidence interval: 1.03–2.00). Prolonged use of progestagens after the age of 40 may be
associated with an increased risk of breast cancer and the subject needs to be investigated further.
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Breast cancer is the most frequent malignancy among women in
Western Europe, North America (Ferlay et al, 2001) and even in
Japan (Minami et al, 2004). The hormonal dependence of breast
cancer has been clearly demonstrated (Dunn et al, 2005) and risk
factors include early age at menarche, nulliparity, late age at first
birth, late age at menopause (Rosner et al, 1994) and the use of oral
contraceptives (OCs) (Collaborative Group on Hormonal Factors
in Breast Cancer, 1996) and hormone replacement therapy (HRT)
(Greiser et al, 2005).
Randomised trials and observational studies have strongly
suggested that some synthetic progestagens, when added to an
oestrogen in HRT, increase breast cancer risk more than the use
of oestrogen alone (Chlebowski et al, 2003; Fournier et al, 2005;
Stefanick et al, 2006). However, data on the impact of the
premenopausal use of progestagens on breast cancer risk are
limited.
As progestagens alone (i.e. not associated with oestrogen) have
long been prescribed in France to premenopausal women for
menstrual disorders, oral contraception, benign uterine and
ovarian diseases and certain benign breast diseases (Lowy and
Weisz, 2005), we have investigated breast cancer risk in relation to
the use of progestagens before menopause in women after the age
of 40 from the E3N cohort.
MATERIALS AND METHODS
E3N is a French prospective cohort set up in 1990 to investigate
cancer risk factors in women. A total of 98995 women, aged 40–64
years, belonging to the MGEN, a French health insurance scheme
primarily covering teachers, and residing in France agreed to be
volunteer by filling in the first questionnaire and a consent form.
Since June 1990, participants have been asked at approximately
2-year intervals to complete self-administered questionnaires
requesting information on various exposures and medical
diagnoses. Information on lifetime use of hormonal treatments,
including progestagens, was first recorded in the January 1992
questionnaire. To facilitate accurate recall, a booklet presenting an
extensive list and colour photographs of the hormonal treatments
marketed in France was mailed to all study participants. Brand
name, age at first use and duration of use were recorded for up to
24 periods of treatment. Information on hormonal treatment use
was updated in each of the subsequent questionnaires. Information
on the dose and the number of treatment days in the cycle was not
requested.
For the present study, the progestagens on which we focused
were oral progestagens prescribed alone before menopause and
after the age of 40 years. In France, progestagens are mainly
prescribed for gynaecological disorders such as breast pain,
uterine or ovarian pathologies and irregular menstruations, for
perimenopausal disorders and for contraception. ‘Mini-pills’,
because they were only occasionally used in our study population,
were classified as OCs and were excluded from the present
analysis.
Cases were identified from self-reports of participants: all
questionnaires asked them whether any cancer had been
diagnosed, requesting the address of their physicians and
permission to contact them to obtain the pathology reports.
For the present study, follow-up started at the date of return of
the second questionnaire (sent out in January 1992). It continued
until the return of the follow-up questionnaire sent out in June
1993, January 1995, April 1997, June 2000 or July 2002, whichever
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diagnosis of cancer or death, whichever occurred first.
Information on date of menopause, type of menopause, date of
last menstruation, date of start of menopausal symptoms and date
of hysterectomy were updated on receipt of each new question-
naire. Women for whom age at menopause could not be
determined (e.g. women who reported a hysterectomy but gave
no information on oophorectomy or menopausal symptoms, or
women who indicated they were postmenopausal without any
other information) were considered as menopausal at age 47 if
menopause was artificial, and at age 51 otherwise, ages that
corresponded in our cohort to the median age at menopause when
artificial and natural, respectively.
Women who had a prevalent cancer other than basal-cell
carcinoma before inclusion (n¼11200) were excluded, as well as
women who had never menstruated (n¼25), those who never
reached the second questionnaire (n¼1066) and those who did
not report either their date at the start of progestagen treatment or
duration (n¼5998). To focus the study on intake of progestagen
during the perimenopause period, the analysis was restricted to
women who had never used a progestagen before the age of 40
and who reached menopause after the age of 40. This left us with
73664 women for the analysis, accruing 668033 person-years, with
an average age at start of follow-up of 51.78 years (standard
deviation (s.d.): 6.8) and a mean follow-up time of 9.07 years
(s.d.: 2.4).
Relative risks (RR) for breast cancer were estimated using Cox
proportional hazards models. Age was used as the timescale.
Known risk factors for breast cancer were included in the model,
as well as confounding variables if they improved model fit by the
Po0.3 criterion; these are indicated in the footnotes of the tables.
Imputation to the mode was used for adjustment factors with 5%
or less of missing values. Progestagen use was included in the
model as a time-dependent variable. The referent group in each
model consisted of women who indicated that they had never used
any progestagen alone before menopause.
Relative risks are given with 95% confidence intervals. The
P-values for assessing possible heterogeneity in effect estimates
were computed from likelihood ratio tests. The P-values for
assessing possible trends were computed from likelihood ratio
tests on continuous variables. All analyses were performed using
SASs system, version 9.1.
RESULTS
The main characteristics of the 73664 women included in the
analysis according to use of progestagen treatment alone are
shown in Table 1. At the end of follow-up, ever users had later
menopause and more frequently had a personal history of benign
disease of the breast, uterus or ovary than never users. Ever use
of OCs (oestrogen–progestagen and mini-pills) or of HRT, and
mammographic follow-up were more frequent in ever users of
progestagens, and young generations were more likely to have
used progestagens than older women.
During follow-up, 2390 cases of new primary invasive breast
cancer were identified among the 73664 women in the cohort.
Pathology reports were obtained for 95.27% of cases. In all, 443802
person-years were associated with never-use and 224231 person-
years with ever-use, in which 1510 and 880 cases of invasive breast
cancer were recorded, respectively. Overall, there was no
significant association between ever-use of progestagen and breast
cancer risk (RR: 1.01; P¼0.77). The relationship between ever-use
of progestagens and breast cancer risk did not vary significantly by
previous use of OC (P for interaction: 0.57), by personal history of
benign breast disease (P for interaction: 0.86), by personal history
of benign uterine or ovarian disease (P for interaction: 0.19) or
mammographic history (P for interaction: 0.23).
However, we found a significant increase in breast cancer risk
with increasing duration of use (P for trend¼0.012, Table 2). We
investigated associations according to time since first use and time
since last use but did not find any significant association or trend
(Table 2).
Table 1 Selected characteristics (at the end of follow-up) of participants
according to ever use of progestagens (n¼73664) E3N cohort study
(1990–2002)
Non-users
n¼45 294
Users
n¼28 370
n (%) n (%)
Year of birth
1925–1937 18402 (40.62) 5030 (17.72)
1938–1944 11024 (24.33) 9109 (32.10)
1945–1951 15868 (35.05) 14231 (50.18)
History of BC (first degree relatives)
None 40191 (88.73) 25027 (88.21)
1 4 640 (10.24) 3 074 (10.83)
2 and + 463 (1.03) 269 (0.96)
History of BC (second degree relatives)
No 38717 (85.47) 23755 (83.73)
Yes 6577 (14.53) 4615 (16.27)
History of BUOD
a
No 27199 (60.04) 14096 (49.68)
Yes 18095 (39.96) 14274 (50.32)
History of BBD
a
No 35122 (77.54) 18418 (64.92)
Yes 10 172 (22.46) 9 952 (35.08)
Body mass index (premenopausal, kg m
 2)
o22 279 (0.61) 148 (0.52)
22–25 43451 (95.93) 27257 (96.07)
25–30 1214 (2.68) 772 (2.72)
430 350 (0.78) 193 (0.69)
Age at menarche (years)
o13 20798 (45.91) 13369 (47.12)
13–15 22653 (50.01) 14134 (49.82)
415 1843 (4.08) 867 (3.06)
Parity
Nulliparous 5450 (12.03) 3028 (10.67)
Age at first FTP430 num¼1
b 1 836 (4.05) 1 101 (3.88)
Age at first FTP430 num41 1981 (4.37) 1129 (3.97)
Age at first FTPo¼ 30 36027 (79.55) 23112 (81.48)
OC use
Never 31606 (69.77) 14927 (52.61)
Ever 13688 (30.23) 13443 (47.39)
Age at menopause
c (years)
o48 9871 (25.23) 4429 (18.24)
48–52 19990 (51.09) 12995 (53.53)
452 9266 (23.68) 6853 (28.23)
HRT use
c
Never 14541 (37.16) 2679 (11.04)
Ever 24 586 (62.84) 21 598 (88.96)
Mammographic history
Never 9660 (21.32) 2775 (9.78)
Ever 35634 (78.68) 25595 (90.22)
aBUOD¼benign uterine or ovarian disease; BBD¼benign breast disease.
bFTP¼Full-term pregnancy; num¼number of FTP.
cAmong postmenopausal
women.
Progestagens and breast cancer risk
A Fabre et al
842
British Journal of Cancer (2007) 96(5), 841–844 & 2007 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yResults on duration of use were further stratified according to
recency of use (Table 3). We found that, among current users, use
longer than 4.5 years was significantly associated with breast
cancer risk (RR¼1.44; P¼0.034), but not use shorter than 4.5
years. After discontinuation, and whatever the duration, the risks
were close to unity. There was no significant trend towards
decreasing risk with increasing time since last use (Table 3).
Because many women (48.4% of progestagens users) changed or
temporarily interrupted their treatment, we verified that this did
not modify risk patterns. Analyses conducted separately on women
who had never interrupted nor changed their treatment and on
women who declared at least one temporary interruption or a
change yielded comparable results (data not shown).
Finally, we investigated associations according to whether
treatment was possibly antigonadotrophic (cyproterone acetate,
medroxyprogesterone acetate, nomegestrol acetate, chlormadinone
acetate, ethynodiol, norethisterone acetate, lynestrenol and pro-
megestone) or not (progesterone, retroprogesterone, medroges-
tone and demegestone). Overall, patterns of risk did not show
marked differences (P for homogeneity: 0.35).
DISCUSSION
We did not find a significant association between breast cancer
risk and ever-use of a progestagen before menopause. However, we
found a significant trend towards increasing risk with increasing
duration of use, and current use of treatment for longer than 4.5
years was positively and significantly associated with risk.
A previous study showed a significant decrease in breast cancer
risk associated with the use of an oral nonsteroid progestin alone
(Plu-Bureau et al, 1994), although based on only 15 cases in a
cohort of 1150 women with benign breast disease, meaning that
any conclusion on the impact of progestins in the general
population was difficult to draw.
Some studies found an increase in risk associated with the use of
a progestagen-only HRT (Magnusson et al, 1999; Newcomb et al,
2002; Beral, 2003; Dinger et al, 2006), but these studies involved
small numbers of cases. Also, the unusual use of a progestagen-
only HRT may reflect the particular profile of the women receiving
such treatment, or even misclassification (underreporting
oestrogen).
Studies on HRT have shown that a combination of oestrogen
plus progestin increases breast cancer risk more than oestrogen
alone (Chlebowski et al, 2003; Fournier et al, 2005; Stefanick et al,
2006), but these involve administration to postmenopausal
women.
In vivo studies have supported a role for progesterone in the
induction of cyclic proliferation in the breast (reviewed in Graham
and Clarke, 1997), although they were not consistent with clinical
trials that found that percutaneous progesterone acts as an
inhibitor of oestrogen-induced proliferation (Chang et al, 1995;
Foidart et al, 1998). In vitro studies have also produced
inconsistent results with progesterone acting as a proliferative
(Edery et al, 1984; McGrath et al, 1985) or an antiproliferative
(Clark and Peck, 1979; McManus and Welsch, 1984; Malet et al,
2000) agent in normal breast cells.
Overall, these results tend to suggest a deleterious effect of oral
progestagens on breast cancer risk. However, different progesta-
gens may affect risk differently, and the estrogenic environment
may also modify their effect (Pasqualini et al, 1998), so it would be
premature to conclude an overall class effect of progestagens,
particularly as studies like ours specifically addressing the
relationship between oral progestagens given alone before
menopause (except for mini pills) and risk are rare.
Our results are consistent with a promoting effect of progesta-
gens on tumour cells, by showing an increase in risk with
Table 2 Relative risk associated with the use of progestagens according
to duration, time since first use and time since last use, compared with
never use (n¼73 664). E3N cohort study (1990–2002)
PY
a Cases RR
a,b 95% CI
a
Never use 443802 1510 1.00
Ever use 224231 880 1.01 0.93–1.11
Duration (years)
c
o1 83449 272 0.90 0.79–1.03
1–2.5 63932 272 1.00 0.85–1.17
2.5–4.5 43712 174 1.10 0.96–1.26
44.5 33138 162 1.13 0.96–1.33
Trend (per year of use) 1.03 1.01–1.06
Interval since first use (years)
c
o4 70591 235 1.03 0.89–1.18
4–7.5 61804 235 1.04 0.90–1.20
7.5–11.5 48026 209 1.04 0.90–1.21
411.5 43810 201 0.95 0.81–1.11
Trend (per year since first use) 0.99 0.98–1.01
Interval since last use (years)
c
Current use 68697 235 1.14 0.97–1.33
o3 68108 265 0.96 0.84–1.10
3–6 40004 175 1.07 0.91–1.26
6–9.5 25511 111 0.97 0.80–1.19
49.5 21863 94 0.92 0.75–1.14
Trend (per year since last use) 0.99 0.98–1.01
aPY¼person-year; RR¼relative risk; CI¼confidence interval.
bAdjusted for BMI
before and after menopause (o22/22-25/25-30/4¼30), menopausal status
1(premenopausal/artificial menopause/natural menopause), age at menopause
(o48/48–52/452), parity and age at first FTP (nulliparous/first FTP at age o 30/
first FTP at age X30, num¼1/first FTP at age X 30, num41), age at menarche
(o13/13–15/415), familial history of breast cancer in sisters, mother, children (no/
1/more than 1), familial history of breast cancer in other relatives (yes/no), personal
history of benign breast disease 1(yes/no), personal history of benign uterin or ovarian
disease (yes/no), use of oral contraceptive (never/current or o 5 years after stop/ 4
5 years after stop), use of HRT 1(No/oestrogen alone/oestrogen+progestin/
oestrogen+progesterone/others) and previous mammography (yes/no) 1Time-
dependent variables.
cCategories correspond to quartiles.
Table 3 Relative risk associated with the use of progestagens according to duration and recency of use, compared with never use (n¼73 664). E3N
cohort study (1990–2002)
Duration of use (years)
o4.5 X4.5
Recency of use [PY; cases] RR
a 95% CI [PY; cases] RR
a 95% CI
Current use [58751;193] 1.09 0.92–1.29 [9 946;42] 1.44 1.03–2.00
Past use [132341;525] 0.97 0.87–1.07 [23 193;120] 1.06 0.88–1.27
Trend (per year since last use) 0.99 0.98–1.01 0.97 0.95–1.01
aAdjusted for the same covariates as in Table 2.
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discontinuation. A similar effect has been demonstrated for depot
medroxyprogesterone acetate (Skegg et al, 1995) and for mini-pills
(Collaborative Group on Hormonal Factors in Breast Cancer, 1996;
Kumle et al, 2002); those authors suggested that recent use was
positively and significantly associated with breast cancer risk, and
that the risk was close to unity after discontinuation. Our results
are in agreement with others (Collaborative Group on Hormonal
Factors in Breast Cancer, 1996, 1997; Lee et al, 2005) suggesting
that the increase in risk might be limited to current use of
hormonal treatments.
Our study had some limitations. We did not record any details
on the treatment (number of days per month, dose) and hence
could not analyse the risk associated with intermittent or
continuous use or with dose. Although the reasons for prescribing
progestagens were not recorded, a potential ‘prescription’ bias is
unlikely, because we adjusted for the variables ‘personal history of
benign breast disease’ and ‘personal history of benign uterine or
ovarian disease’, and because the effect of progestagens on breast
cancer risk did not vary significantly by personal history of benign
breast disease or by personal history of benign uterine or ovarian
disease. The effect of progestagens on breast cancer risk did not
differ significantly according to OC use. Misclassification of
progestagen exposure, which was based on self-reported informa-
tion, may have affected our results, but given the prospective
design, this should be non-differential between cases and non-
cases, and would tend to reduce the magnitude of the relationship
with risk, and dampen differences in the effects of different
progestagens.
Finally, there is limited scope for ‘surveillance bias’ owing to
progestagen users being more likely to have repeated mammo-
grams, because this was adjusted for, and because the effect of
progestagens on risk did not differ significantly according to
mammographic history.
In conclusion, our study suggests that the use, before
menopause, of oral progestagens (without oestrogens) by women
over 40 may increase breast cancer risk. Further follow-up study
will enable more exhaustive analysis using specific categories of
progestagens.
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